written on 23.09.2021
China Biopharma Dealmaking Review H1 2021
Similar Facts and Figures
The Greater Bay Area (Guangdong, Hong Kong, Macau) Macroeconomic Snapshot
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
China / New Drug Approvals List 2020
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
China Pharma Forecast 2019-2023
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
China / Top 10 Pharma Companies 2020
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Pharma Manufacturing and R&D in China and India: A Comparison
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
China Biosimilar Market Snapshot
Become a PharmaBoardroom Member for free to access this contentJoin the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password…
Latest Report
China / Emerging Pharmacovigilance Framework Ensuring Safe COVID-19 Vaccines
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
China / 61.7% Profit Hit Needed for NDRL Listing; Local mRNA Rush; BioNTech Continues Push for Vaccine Approval
Some of the biggest stories across China’s healthcare and life science industry today, including the 61.7 percent average price reduction Big Pharma took to get their drugs listed on China’s…
Global / PharmaBoardroom’s Top Five Op-Eds of 2021
PharmaBoardroom’s network of thought leaders provided some of our best-read content in 2021 on topics ranging from China’s National Reimbursement Drug List to the vaccine row that erupted between AstraZeneca…
